Dublin, Sept. 18, 2023 (GLOBE NEWSWIRE) -- The "Radiopharmaceutical Theranostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type, Radioisotope, Source, Application, Indication, and End User" report has been added to ResearchAndMarkets.com's offering.
The global radiopharmaceutical theranostics market is projected to witness substantial growth, reaching $3,441.97 million by 2028 from $1,814.58 million in 2022, with a robust Compound Annual Growth Rate (CAGR) of 11.3% during the period from 2022 to 2028.
The market's expansion is driven by the increasing incidence of cancer and the growing application of radiopharmaceutical theranostics in treating cardiovascular disorders.
Radiopharmaceuticals play a crucial role in both the diagnosis and therapy of cancer, making them a cornerstone in the fight against this disease. They enable clinicians to diagnose specific types and stages of cancer, providing essential information for treatment planning. Moreover, radiopharmaceuticals are integral to targeted therapies, ensuring precise and effective treatment while minimizing harm to healthy tissues.
The adoption of radiopharmaceutical theranostics has expanded into various areas of medicine. For instance, they are now used in treating cardiovascular disorders. The combination of therapeutic and diagnostic techniques, known as theranostics, has paved the way for personalized medicine. It has allowed for more tailored and effective treatments, such as radionuclide therapy for advanced prostate cancer and neuroendocrine tumors.
While the market holds significant growth potential, regulatory challenges related to the approval of radiopharmaceutical theranostics remain a hurdle. Nevertheless, the rising prevalence of cancer worldwide and the promising applications of radiopharmaceutical theranostics in personalized medicine continue to drive market growth.
Companies Mentioned
- Bayer AG
- GE HealthCare Technologies Inc
- Curium
- Lantheus Medical Imaging, Inc.
- Telix Pharmaceuticals Ltd.
- Cardinal Health Inc
- Advanced Accelerator Applications S.A.
- Jubilant Radiopharma
- Theragnostics
- NuView Life Sciences
Key Market Insights:
- Product Type: The positron emission tomography (PET) tracers segment is expected to register the highest CAGR during the forecast period. PET tracers offer higher resolution and quantification of activity, making them a preferred choice for imaging techniques.
- Radioisotope: Lutetium (Lu) 177 is anticipated to witness the highest CAGR. It is increasingly used in targeted radionuclide therapy for cancer, including prostate cancer and neuroendocrine tumors.
- Source: Cyclotrons are expected to dominate the source segment. They are well-suited for producing radionuclides used in medical imaging techniques, particularly PET.
- Application: The oncology segment is likely to hold the largest market share. Radiopharmaceutical theranostics have a significant impact on cancer treatment, offering targeted therapeutic solutions for various types of cancer.
- End User: Hospitals currently dominate the market. However, academic and research institutes are expected to grow at the highest CAGR during the forecast period, driven by research activities and technological advancements.
The global radiopharmaceutical theranostics market is poised for substantial growth, driven by the increasing prevalence of cancer and the expanding applications of radiopharmaceuticals in personalized medicine.
Key Attributes:
Report Attribute | Details |
No. of Pages | 185 |
Forecast Period | 2022 - 2028 |
Estimated Market Value (USD) in 2022 | $1814.58 million |
Forecasted Market Value (USD) by 2028 | $3441.97 million |
Compound Annual Growth Rate | 11.3% |
Regions Covered | Global |
Key Topics Covered:
1. Introduction
2. Radiopharmaceutical Theranostics Market - Key Takeaways
3. Research Methodology
4. Radiopharmaceutical Theranostics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.3 Expert's Opinion
5. Radiopharmaceutical Theranostics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Incidence of Cancer
5.1.2 Rising Application in Treatment of Cardiovascular Disorders
5.2 Market Restraints
5.2.1 Regulatory Challenges for Approval of Radiopharmaceutical Theranostics
5.3 Market Opportunities
5.3.1 Theranostic Digital Twins for Personalized Radiopharmaceutical Therapies
5.4 Future Trends
5.4.1 Radiopharmaceutical Theranostics in Nuclear Medicine
5.5 Impact Analysis
6. Radiopharmaceutical Theranostics Market - Global Analysis
6.1 Global Radiopharmaceutical Theranostics Market Revenue Forecast and Analysis
6.2 Global Radiopharmaceutical Theranostics Market, by Geography - Forecast and Analysis
6.3 Market Positioning of Key Players
6.3.1 GE HealthCare Technologies Inc
6.3.2 Curium
7. Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - by Product Type
7.1 Overview
7.2 Global Radiopharmaceutical Theranostics Market Revenue Share, by Product Type 2021 & 2028 (%)
7.2.1 Positron Emission Tomography (PET) Tracers
7.2.1.1 Overview
7.2.1.2 Positron Emission Tomography (PET) Tracers: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
7.2.2 Beta Emitters
7.2.2.1 Overview
7.2.2.2 Beta Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
7.2.3 Alpha Emitters
7.2.3.1 Overview
7.2.3.2 Alpha Emitters: Global Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 (US$ Million)
8. Global Radiopharmaceutical Theranostics Market Analysis - by Radioisotope
9. Global Radiopharmaceutical Theranostics Market Analysis - by Source
10. Global Radiopharmaceutical Theranostics Market Analysis - by Application
11. Global Radiopharmaceutical Theranostics Market Analysis - by Indication
12. Global Radiopharmaceutical Theranostics Market Analysis - by End User
13. Radiopharmaceutical Theranostics Market - Revenue and Forecast to 2028 - Geographic Analysis
14. Impact Of COVID-19 Pandemic on Radiopharmaceutical Theranostics Market
15. Radiopharmaceutical Theranostics Market - Industry Landscape
15.1 Overview
15.2 Growth Strategies in the Radiopharmaceutical Theranostics Market
15.3 Inorganic Growth Strategies
15.3.1 Overview
15.4 Organic Growth Strategies
15.4.1 Overview
16. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/m4s6ot
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment